You searched for "stone"
Focal therapy for prostate cancer – ready for prime time?
The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...Action Bladder Cancer UK urges health professionals to help raise awareness during Bladder Cancer Awareness Month in May
Action Bladder Cancer UK is calling on health professionals – including specialist urology and cancer nurses, urologists, oncology and radiology health professionals and others, to support Bladder Cancer Awareness Month by helping to raise awareness of the symptoms of bladder...Core Surgical Training
With competition ratios for core surgical training (CST) rising to 9 to 1, career progression and job security are an ever-increasing stress for resident doctors [1]. Of the 630 jobs available in 2025, only a small fraction of these will...Workshop news update from the upcoming BAUN Conference at the ACC in Liverpool on 4 - 5 November
The British Association of Urological Nurses (BAUN) Conference 2024 takes place from 4-5 November at the ACC in Liverpool. In addition, popular pre-conference workshops are taking place on Sunday 3 November.
Outcomes of renal cancer surgery on renal function and mortality on those with and without CKD
In urology we are encountering an ageing and more comorbid population, including a group of patients with chronic kidney disease (CKD). In this retrospective study, a group from the Cleveland Clinic present the extended follow-up of patients with and without...
Is TRUS and biopsy obsolete as a diagnostic test for prostate cancer: refining the perineal biopsy technique?
Whilst there has been a dramatic shift in how patients are investigated for potential prostate cancer, transrectal ultrasound (TRUS) and biopsy remains the most commonly used technique for tissue sampling. In this single centre, retrospective analysis, 634 men, over a...
Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?
Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...
